Q2 2025 EPS Estimates for ResMed Inc. (NYSE:RMD) Raised by Analyst

ResMed Inc. (NYSE:RMD) – Equities researchers at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of ResMed in a research note issued on Tuesday, September 10th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.19 for the quarter, up from their previous estimate of $2.16. The consensus estimate for ResMed’s current full-year earnings is $8.91 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.23 EPS, Q4 2025 earnings at $2.29 EPS, FY2025 earnings at $8.72 EPS, Q2 2026 earnings at $2.26 EPS, Q4 2026 earnings at $2.45 EPS, FY2026 earnings at $9.29 EPS and FY2027 earnings at $10.15 EPS.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. ResMed had a net margin of 21.79% and a return on equity of 25.00%. ResMed’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.60 earnings per share.

Several other equities analysts have also recently weighed in on the company. KeyCorp raised their price target on ResMed from $238.00 to $251.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Needham & Company LLC cut shares of ResMed from a “buy” rating to a “hold” rating and set a $236.00 price target on the stock. in a research report on Wednesday, September 4th. StockNews.com cut shares of ResMed from a “buy” rating to a “hold” rating in a research note on Friday, August 30th. Royal Bank of Canada increased their price target on shares of ResMed from $204.00 to $206.00 and gave the company a “sector perform” rating in a report on Friday, August 2nd. Finally, Citigroup cut ResMed from a “buy” rating to a “neutral” rating in a research note on Monday, June 24th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $204.70.

ResMed Trading Up 1.3 %

Shares of ResMed stock opened at $252.82 on Wednesday. ResMed has a twelve month low of $132.24 and a twelve month high of $255.18. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average price of $218.37 and a 200-day moving average price of $205.73. The firm has a market cap of $37.15 billion, a price-to-earnings ratio of 38.84, a PEG ratio of 2.44 and a beta of 0.69.

Hedge Funds Weigh In On ResMed

A number of large investors have recently bought and sold shares of RMD. Atlantic Edge Private Wealth Management LLC bought a new position in shares of ResMed in the 4th quarter worth $27,000. OFI Invest Asset Management bought a new position in ResMed in the second quarter worth about $32,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of ResMed during the first quarter valued at about $35,000. Versant Capital Management Inc boosted its holdings in shares of ResMed by 196.7% in the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 120 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new position in shares of ResMed in the 2nd quarter worth approximately $37,000. Institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $248.38, for a total transaction of $3,646,963.54. Following the completion of the sale, the chief executive officer now owns 464,169 shares in the company, valued at approximately $115,290,296.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $248.38, for a total value of $3,646,963.54. Following the completion of the sale, the chief executive officer now directly owns 464,169 shares in the company, valued at $115,290,296.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Justin Leong sold 48,000 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the completion of the sale, the insider now directly owns 18,741 shares of the company’s stock, valued at $4,068,108.87. The disclosure for this sale can be found here. Insiders have sold a total of 97,931 shares of company stock worth $21,382,007 over the last quarter. Company insiders own 1.21% of the company’s stock.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.84%. The ex-dividend date is Thursday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio is 32.57%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.